Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Combined Treatment for Non-Healing Wounds in Chronic Lower Extremity Arterial Disease: A Comparative Study

28. September 2026 aktualisiert von: Azat Chinaliyev, Tulip Medicine

Effectiveness of Combined Treatment Methods for Non-Healing Wounds in Patients With Chronic Lower Extremity Arterial Disease: A Comparative Study

Endovascular interventions, such as balloon angioplasty and stenting, are commonly used for PAD due to their proven safety and effectiveness. However, traditional treatments for chronic non-healing wounds are often insufficient. Advances in cell biotechnology, particularly fibroblast therapy, show promise for enhancing wound healing, as fibroblasts play a crucial role in tissue repair and inflammation.

This study aims to develop, assess, and evaluate the safety of a combined treatment approach that incorporates fibroblast therapy with existing methods for managing chronic non-healing wounds in PAD patients.

Studienübersicht

Detaillierte Beschreibung

Chronic obliterative diseases of the lower extremity arteries, or peripheral artery disease (PAD), result from systemic atherosclerosis and affect about 202 million adults globally. This condition, marked by progressive arterial stenosis or occlusion, is associated with significant risk factors such as diabetes, smoking, and hypertension. PAD can lead to symptoms ranging from pain and fatigue to severe complications like non-healing chronic wounds. These wounds impose a substantial economic burden on healthcare systems and significantly impact patients' quality of life.

In some countries, over 2.5 million people suffer from chronic non-healing ulcers, with high rates of recurrence and poor healing outcomes. Managing these wounds is costly, with significant indirect costs due to loss of productivity. Post-amputation survival rates are low, and traditional treatments often fail to fully address the issue.

Endovascular interventions, such as balloon angioplasty and stenting, are preferred for PAD due to their safety and effectiveness. However, current methods for treating chronic non-healing wounds remain insufficient. Recent advancements in cell biotechnology, particularly fibroblast therapy, show promise for improving wound healing. Fibroblasts play a key role in tissue repair and inflammation.

There is a need for more research on the effectiveness of combining fibroblast therapy with existing treatments for chronic non-healing wounds in PAD patients. Addressing this gap could lead to better treatment outcomes and improved quality of life for affected individuals.

The aim of this study is to develop, assess the effectiveness, and evaluate the safety of a combined treatment method for managing chronic non-healing wounds in patients with chronic obliterative disease of the lower extremity arteries.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

116

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Astana, Kasachstan, 010000
        • National Research Oncology Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Male and female patients aged 18 to 75 years inclusive.
  2. Patients with a history of confirmed stable intermittent lameness, the symptoms of which have been observed continuously for at least 3 months at the time of randomization.
  3. Patients with a diagnosis of PAD (code I 70.2 - I 70.9 according to the International Classification of Diseases, 10th revision [ICD - 10]), confirmed by the results of ultrasound duplex scanning of blood vessels.
  4. Patients whose smoking status remained stable for at least 3 months prior to randomization (for smokers).
  5. Patients with an ankle - brachial Doppler index value at rest ≤0.9.
  6. Patients with a long-term non-healing wound (more than 1 month) and intermittent claudication with a pain-free walking distance of less than 200 meters.
  7. Patients who, in the opinion of the investigator, are able to understand and comply with the study requirements.
  8. Before starting any examination procedures by the patient or, if applicable, its legal representative, a signed and dated written informed consent form, as well as any necessary processing permissions personal data.

Exclusion Criteria:

  1. Acute myocardial infarction (ACS), acute cerebrovascular accident (stroke)
  2. Pulmonary embolism (PE)
  3. Acute infectious diseases
  4. Patients who underwent reconstructive intervention on the arteries of the lower extremities (surgical or intravascular) in the last 3 months before randomization.
  5. Patients who underwent major cardiac surgery within 6 months prior to randomization.
  6. Patients with congestive heart failure III-IV functional class according to classification of the New York Heart Association.
  7. Patients with any other disease that significantly limits physical activity, or any other medical condition that, in the opinion of the investigator, may limit the patient's participation in the study.
  8. Patients with mental status disorders
  9. Patients with a history of hypersensitivity or allergy to a radiopaque substance, similar drugs or excipients.
  10. Patients who are pregnant or breastfeeding, or who plan to become pregnant before participating in this study or during the study, or who intend to become an egg donor within the same period of time.
  11. Progression of the underlying and concomitant disease
  12. High levels of creatinine and urea in a biochemical blood test (creatinine in women: more than 80.0 µmol / l; men: more than 110.0 µmol / l; ); ( Urea in adults under 60 years of age is more than 8.32 mmol/l, adults over 60 years of age are more than 7.5 mmol/l )
  13. Presence of peptic ulcer of the stomach and duodenum (DUD)
  14. Patients with total thrombosis of the vessels of the lower extremities

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: combined treatment

Combined treatment (balloon angioplasty or stenting + fibroblast transplantation).

A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest. After surgery, fibroblasts will be applied to the wound for 24 hours.

Aktiver Komparator: Endovascular treatment

Endovascular interventions + traditional debridement.

A balloon or a stent of the required size (according to the intrinsic diameter of the affected vessel) is delivered to the affected area, sequential balloon dilatation with exposure of up to 5 minutes or stenting of the vessel is performed. After completion, control angiography is performed with evaluation of the result. Instruments, introdjuncer are removed. Manual compression haemostasis (up to 20 minutes over the puncture site) followed by aseptic pressure dressing on the puncture site for 12 hours with bed rest.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
brachial-shoulder index
Zeitfenster: 1 day, after 1 month, after 3 month, after 6 month

The Brachial-Shoulder Index (BSI, ratio) is a diagnostic measure used to assess blood flow and detect potential vascular abnormalities. It is calculated by dividing the systolic blood pressure (mmHg) at the shoulder by the systolic blood pressure (mmHg) at the arm (brachial artery). This index helps evaluate the presence of arterial blockages or compression between the shoulder and the arm, which can indicate peripheral vascular disease or other circulatory issues. A reduced BSI may suggest impaired blood flow (mm/sec) and is useful in diagnosing conditions related to upper limb circulation.

1 day, after 1 month, after 3 month, after 6 month

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
dynamics of wound healing
Zeitfenster: 1 day, after 1 month, after 3 month, after 6 month

The dynamics of wound healing refer to the process and progression of tissue repair following an injury. This process involves several key phases:Hemostasis, Inflammation, Proliferation, Maturation. The rate and quality of healing can be influenced by factors such as wound type, underlying health conditions, and treatment methods. Monitoring these dynamics ( in cm^2) helps assess the effectiveness of interventions and guide clinical decisions

1 day, after 1 month, after 3 month, after 6 month

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of participants
Zeitfenster: in a month, 3 months, 6 months

The number of participants in the study will be analyzed.

in a month, 3 months, 6 months
Analysis of participants' body weight
Zeitfenster: in a month, 3 months, 6 months

Participants' body weight will be analyzed

in a month, 3 months, 6 months
Assessment of the degree of oxygen saturation of the lower extremities
Zeitfenster: in a month, 3 months, 6 months

During the study, the oxygen saturation level of the lower extremities will be assessed using a peripheral pulse oximeter. Since ischemia of the extremities affects the oxygen saturation level of the surrounding tissues.

in a month, 3 months, 6 months
Results of the SF-12 questionnaire
Zeitfenster: before the tretment, 3 months, 6 months

Before treatment, then 3 and 6 months after treatment, participants will complete the SF-12 questionnaire, which will take into account the physical condition, mental state and general condition of the participants.

before the tretment, 3 months, 6 months
Activity of Daily Living Index - Bartell Index.
Zeitfenster: before the tretment, 3 months after the treatment, 6 months after the treatment

The Barthel scale is an ordinal scale used to measure performance in daily living. Each performance element is rated on this scale with a set number of points assigned to each level or ranking. It uses ten variables that describe ADLs and mobility. A higher number is associated with a greater likelihood that you will be able to live at home with a degree of independence after discharge from the hospital.

before the tretment, 3 months after the treatment, 6 months after the treatment

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

9. Januar 2023

Primärer Abschluss (Tatsächlich)

10. Juli 2025

Studienabschluss (Tatsächlich)

6. September 2025

Studienanmeldedaten

Zuerst eingereicht

11. Juni 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

4. Dezember 2024

Zuerst gepostet (Tatsächlich)

9. Dezember 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

1. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

28. September 2026

Zuletzt verifiziert

1. Juli 2025

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren